Par-4 and Telomere-telomerase System in Type 2 Diabetes Patients Who Received GLP-1 or Metformin Treatment

NCT02535299 · Unknown status

Last updated 2026-05-28

This clinical trial is studying how GLP-1 or metformin treatment affects certain biological markers, like the Par-4 protein and the telomere-telomerase system, in people with type 2 diabetes.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 200 people Planned (estimated).

Who can join Ages 18–75 · all sexes Healthy volunteers accepted.

Timeline Started 2016-06 · est. completion 2019-12

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT02535299 ↗

Description as written by the study sponsor.

Objectives: To investigate the treatment effect between insulin,metformin and Liraglutide; in Type 2 Diabetes in our hospital, in order to investigate the possible mechanism about telomere-telomerase system and Par-4.

Treatments tested

Liraglutide also known as Victoza Drug

GLP-1 analog (1.2mg-1.8mg/day) treatment for 6 months
Metformin also known as Glucophage Drug

Metformin(1500mg-2000mg/day) treatment for 6 months

Main thing measured	physiological parameter:glycosylated hemoglobin A1c
Sponsor	Third Military Medical University
Conditions studied	GLP-1；Metformin；Telomere-telomerase System；Par-4
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02535299 ↗